Catalent Inc. | Balance Sheet

Fiscal year is July-June. All values USD Millions.
2014
2015
2016
2017
2018
Cash & Short Term Investments
74
151
132
307
410
Total Accounts Receivable
404
372
415
489
568
Inventories
135
133
155
185
209
Other Current Assets
75
81
89
79
53
Total Current Assets
688
738
790
1,060
1,240
Net Property, Plant & Equipment
873
885
906
996
1,271
Intangible Assets
1,455
1,430
1,291
1,317
1,942
Other Assets
49
28
22
28
45
Total Assets
3,090
3,145
3,091
3,454
4,531
ST Debt & Current Portion LT Debt
25
24
28
25
72
Accounts Payable
148
128
144
163
192
Income Tax Payable
63
57
39
25
26
Other Current Liabilities
217
190
181
257
287
Total Current Liabilities
453
399
391
469
577
Long-Term Debt
2,685
1,864
1,833
2,055
2,649
Provision for Risks & Charges
155
144
151
130
132
Deferred Taxes
77
8
42
22
-
Other Liabilities
61
43
39
46
54
Total Liabilities
3,458
2,506
2,455
2,731
3,444
Common Equity (Total)
371
634
636
724
1,087
Total Shareholders' Equity
371
634
636
724
1,087
Total Equity
367
640
636
724
1,087
Liabilities & Shareholders' Equity
3,090
3,145
3,091
3,454
4,531
Accumulated Minority Interest
4
6
-
-
-

About Catalent

View Profile
Address
14 Schoolhouse Road
Somerset New Jersey 08873
United States
Employees -
Website http://www.catalent.com
Updated 07/08/2019
Catalent, Inc. is a holding company, which engages in the provision of delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. It operates through the following segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment focuses on the formulation, development, and manufacture of prescription and consumer health soft capsules, softgels, vegicaps and optishell capsules.